Liang Zhu

US Patent:

8114982, Feb 14, 2012

Filed:

Nov 28, 2007

Appl. No.:

12/312616

Inventors:

Liang Zhu - Ardsley NY, US
Daqian Sun - Bronx NY, US

Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

C07H 21/04

US Classification:

536 245, 536 2431, 536 241, 514 44

Abstract:

Provided are DNAs comprising a polynucleotide that encodes at least a first modified miR- precursor and a second modified miR- precursor. Also provided are vectors comprising the the DNAs, where the vector can replicate in a host cell. Additionally, specific lentiviral vectors comprising the above-described DNA are provided, as are methods of inhibiting expression of a target gene in a eukaryotic cell.

US Patent:

8173604, May 8, 2012

Filed:

May 23, 2007

Appl. No.:

12/226935

Inventors:

Liang Zhu - Ardsley NY, US
Peng Ji - Watertown MA, US

Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

A61K 38/10
A61K 38/16

US Classification:

514 214

Abstract:

Methods of killing a cancer cell are provided. Also provided are methods of treating a subject having a cancer. Additionally, compounds are provided that comprise a peptide from about 18 to about 100 amino acids or peptidomimetics comprising the sequence of SEQ ID NO:1. Additionally provided are methods of screening an agent for the ability to kill a cancer cell.

US Patent:

20110178156, Jul 21, 2011

Filed:

Jan 19, 2011

Appl. No.:

12/930861

Inventors:

Liang Zhu - Ardsley NY, US

International Classification:

A61K 31/713
A61P 35/00
C12Q 1/48
G01N 33/53

US Classification:

514 44 A, 435 15, 435 71

Abstract:

The present invention provides methods of determining a putative agent that inhibits tumorigenesis in retinoblastoma protein deficient cells, the methods comprising determining whether the putative agent decreases phosphorylation of threonine residue 187 of p27, decreases S-phase kinase-associated protein 2 interaction with p27 having a phosphorylated threonine residue 187, or an increase in apoptosis of retinoblastoma protein deficient cells. The present invention also provides the agent, the pharmaceutical composition, and methods of inhibiting, preventing and treating tumorigenesis in retinoblastoma deficient cells, the method comprising administration of the agent that decreases phosphorylation of threonine residue 187 of p27 or the S-phase kinase-associated protein 2 interaction with p27 having a phosphorylated threonine residue 187.

US Patent:

20110189192, Aug 4, 2011

Filed:

Feb 19, 2009

Appl. No.:

12/918099

Inventors:

Alan B. Cooper - Kenilworth NJ, US
Yang Nan - Cambridge MA, US
Yongqi Deng - Cambridge MA, US
Neng-Yang Shih - Cambridge MA, US
Hugh Y. Zhu - Kenilworth NJ, US
Joseph M. Kelly - Kenilworth NJ, US
Subrahmanyam Gudipati - Kenilworth NJ, US
Ronald J. Doll - Kenilworth NJ, US
Mehul F. Patel - Cambridge MA, US
Jagdish A. Desai - Kenilworth NJ, US
James J-S Wang - Kenilworth NJ, US
Sunil Paliwal - Kenilworth NJ, US
Sobhana Babu Boga - Kenilworth NJ, US
Abdul-Basit Alhassan - Kenilworth NJ, US
Xiaolei Gao - Kenilworth NJ, US
Liang Zhu - Cambridge MA, US
Xin Yao - Kenilworth NJ, US

International Classification:

A61K 31/444
C07D 401/14
C07D 409/14
C07D 417/14
A61K 31/501
A61K 39/395
A61K 31/7052
A61P 35/02
A61P 35/00

US Classification:

4241581, 546256, 544238, 514333, 51425203, 514 43, 4241721

Abstract:

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.